PSA-density does not appear to significantly improve its diagnostic performance.
Bi-parametric prostate MR (bp-MR) aids in detection of clinically significant prostate cancer (PCa), according to a study published in the European Journal of Radiology. Contrary to findings in the recent literature, PSA-D does not appear to significantly improve its diagnostic performance.
Researchers from Italy retrospectively analyzed 334 patients to evaluate the diagnostic performance of bp-MR, PSA-density (PSA-D) and their combination in biopsy-naïve patients.
All patients had undergone prostate MR on a 3T scanner. A total of 114 patients who underwent TRUS-biopsy within 30â¯days following MR with no previous prostate biopsies were included in the results. The researchers assessed three scenarios:
• Detection of lesions independently of ISUP score (ISUPâ¯≥â¯1)
• Detection of both intermediate and clinically significant lesions (ISUPâ¯≥â¯2)
• Detection of clinically significant lesions alone (ISUPâ¯≥â¯3).
The results showed that in all evaluated scenarios, bp-MR showed a significantly higher predictive power (AUCâ¯=â¯0.87 to 0.95) compared to the performance of PSA-D (AUCâ¯=â¯0.73 to 0.79), while their combination (AUCâ¯=â¯0.91 to 0.95) showed no statistically significant improvement compared to bp-MR alone.
The researchers concluded their results confirmed that bp-MR is a powerful tool in detection of clinically significant PCa. They also noted that contrary to findings in the recent literature, PSA-D does not appear to significantly improve its diagnostic performance.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
Can a Dual-Energy CT Model Bolster Breast Cancer Detection?
July 12th 2024Incorporating age, lesion shape and effective atomic number in the venous phase of dual-energy CT (DECT), an emerging model demonstrated a 79.1 percent AUC for differentiating between malignant and benign breast lesions.
A Victory for Radiology: New CMS Proposal Would Provide Coverage of CT Colonography in 2025
July 12th 2024In newly issued proposals addressing changes to coverage for Medicare services in 2025, the Centers for Medicare and Medicaid Services (CMS) announced its intent to provide coverage of computed tomography colonography (CTC) for Medicare beneficiaries in 2025.